CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 19 enrolled
Drug / intervention
NPH +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01461616
NCT01461616Phase 3Completed
CompareCT.gov

Effect of NPH Insulin, Insulin Detemir and Insulin Glargine on IGFBP-1 Production and Serum IGF-I in Subjects With Type 1 Diabetes Mellitus: An Open-label, Randomised, Triple Cross-over Trial

University of Aarhus·interventional·Posted Oct 28, 2011·Updated Dec 4, 2012

In Brief

A Phase 3 clinical trial evaluating NPH, Detemir, and 1 other intervention for Diabetes Mellitus, Type 1. Completed, enrolled 19 participants across 1 site.

Detailed Summary

The objective is to describe the interaction of equal doses of NPH insulin (Neutral Protamine Hagedorn), insulin Detemir and insulin glargine on IGFBP-1 (Insulin-like Growth Factor Binding Protein-1) production as well as immunoreactive and bioactive IGF-I (Insulin-like Growth Factor-I) after once-daily injection on three separate visits in type 1 diabetic subjects.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsDiabetes Mellitus, Type 1
CountriesDenmark
Collaborators--

Timeline

Phase 3CompletedFinished
201220132014201520162017201820192020202120222023202420252026
First PostedOct 28, 2011
Enrollment StartFeb 1, 2012
Primary CompletionNov 1, 2012
TodayJul 2, 2026
Enrollment to primary: 9 monthsPosted 14.7 years ago

Interventions

NPHdrug

equal doses of NPH insulin, insulin Detemir and insulin glargine injection

Detemirdrug

equal doses of NPH insulin, insulin Detemir and insulin glargine injection

Glarginedrug

equal doses of NPH insulin, insulin Detemir and insulin glargine injection